Skip to main content
. 2023 Apr 17;7:55. [Version 1] doi: 10.12688/gatesopenres.14511.1

Table 2. Factors that may influence the feasibility of different vaccine options.

OPV
formulation		 Sabin OPV Novel OPV Comments
OPV1 mOPV1 currently licensed and
available 		nOPV1 development under way and
likely available by the time of potential
restart 		 
OPV2 mOPV2 currently licensed and
available 		nOPV2 currently available under EUL
and likely licensed by the time of
potential restart 		No use of OPV in RI is currently permitted,
and declaration of tOPV-bOPV switch
failure is a prerequisite for changing this
prohibition
OPV3 mOPV3 currently licensed and
available 		nOPV3 development under way and
likely available by the time of potential
restart 		 
OPV12 Sequential or coadministration
of mOPV1 and mOPV2 possible

New bivalent formulation of
Sabin OPV12 would require
licensure 		Sequential or coadministration of
nOPV1 and nOPV2 would require
licensure

bnOPV12 would require licensure		 Sequential administration of mOPV1 and
nOPV2 possible

Sequential or coadministration of nOPV1
and mOPV2 would require licensure

Mixed Sabin and novel bivalent formulation
of OPV12 would require licensure
OPV13 bOPV currently licensed and
available 		Sequential or coadministration of
nOPV1 and nOPV3 would require
licensure

bnOPV13 would require licensure		 Sequential or coadministration of mOPV1
and nOPV3 or nOPV1 and mOPV3 would
require licensure

Mixed Sabin and novel bivalent formulation
of OPV13 would require licensure
OPV23 Sequential or coadministration
of mOPV2 and mOPV3 possible

New bivalent formulation of
Sabin OPV23 would require
licensure 		Sequential or coadministration of
nOPV2 and nOPV3 would require
licensure

bnOPV23 would require licensure		 Sequential administration of mOPV3 and
nOPV2 possible

Sequential or coadministration of nOPV3
and mOPV2 would require licensure

Mixed Sabin and novel bivalent formulation
of OPV23 would require licensure
OPV123 tOPV currently licensed and
available 		Sequential or coadministration of
nOPV1 and nOPV2 and nOPV3 would
require licensure

tnOPV would require licensure		 Sequential administration of bOPV and
nOPV2 possible

Any other mixed Sabin and novel OPV
formulation would require licensure

Abbreviations:

EUL, emergency use listing; OPV, oral poliovirus vaccine; mOPVk, monovalent type k Sabin OPV, where k=1,2 or 3; nOPVk, monovalent type k novel OPV, where k=1,2 or 3;

bOPV, bivalent types 1 and 3 Sabin OPV; tOPV, trivalent types 1, 2 and 3 Sabin OPV; bnOPVx,y, potential future bivalent novel OPV, where x,y={12,23,13;

tnOPV, potential future trivalent novel OPV